Merrion Pharmaceuticals Appoints Dr. Hing Kin Chan as Chief Business Officer

Merrion Pharmaceuticals Appoints Dr. Hing Kin Chan as Chief Business Officer

Dublin, Ireland 14th May 2010 - Merrion Pharmaceuticals plc (MERR:ESM) today announced the appointment of Dr. Hing Kin Chan as Chief Business Officer. Dr Chan will be responsible for Merrion's Business Development Operations.

Dr Chan has over 20 years successful commercial and business development experience in the healthcare industry. Prior to joining Merrion, Dr Chan was the Chief Business Officer at DBV Technologies in Paris, Vice President of Commercial Development at ProBioGen, Berlin and Business Development Director for Eurand, Milan.

Throughout his career, Dr Chan has had strategic responsibility for all business sectors and the development of commercial strategies in the drug delivery business sector. Dr Chan is highly experienced in deal making and negotiations along with identification of new opportunities and portfolio fits within the pharmaceutical industry. Dr Chan has successfully negotiated numerous deals and licensing agreements with large healthcare organisations and has a wealth of global management experience.

Commenting on the appointment John Lynch, CEO, Merrion Pharmaceuticals said "We welcome Hing Kin Chan to the Merrion team and we look forward to benefiting from his vast experience in this sector in the coming years. He brings to Merrion a long track record of success, at a time of considerable opportunity for Merrion to achieve the significant goals we've set".

Dr Chan holds a PhD in Pharmacy from the University of Geneva and a B Pharm Hons from the University of London as well as a Diploma in Business Administration from Henley Management College. Fluent in four languages, Dr Chan is also a member of the Royal Pharmaceutical Society (MRPS) in the United Kingdom and The Gerson Lehrman Group Healthcare Council.

Media Enquiries:

Merrion Pharmaceuticals plc
Jonathan O'Connell
+353 1 672 9272
www.merrionpharma.com

Brunswick Group
Jon Coles
Will Carnwath
T +44 207 404 5959
[email protected]

Griffin Integrated Communications
Daniel O'Connell
T 212.481.3456, ext 16
F 212.684.0606
[email protected]

About Merrion:

Merrion Pharmaceuticals (www.merrionpharma.com) is engaged in the development of oral forms (tablets/capsules) of drugs that have poor absorption and are generally given by injection. Merrion was established in 2003 to commercialize various technologies acquired from Elan Corporation, plc. Merrion Pharmaceutical's patented drug delivery technologies increase bioavailability, by improving absorption in the gastrointestinal tract, of drugs that are otherwise poorly absorbed. This can provide substantial benefit in patient convenience and safety, and might also provide enhanced drug efficacy. Merrion utilizes its technology to develop new oral drugs in two ways; it develops its own proprietary drugs using GIPET and partners with other pharmaceutical companies in developing oral GIPET formulations of their products. Merrion is listed on the Dublin Stock Exchange under the symbol MERR.

Suggested Articles

After its recent $4.8 billion buyout of gene therapy specialist Spark Therapeutics, Roche is now handing over one of its execs as its CMO.

Halozyme CEO Helen Torley discusses how the company stayed alive after its lead program, a treatment for pancreatic cancer, failed in phase 3.

The under-active genes that cause heart problems and poor muscle movement in Down syndrome may also impede the growth of solid tumors, a study found.